Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiahong Zhong

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Frontiers in Pharmacology|November 11, 2024
Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)Jiahong Zhong, Xihui Yu, Zhuomiao Lin
Peerj|February 3, 2025
Phosphodiesterase 4 inhibition as a novel treatment for strokeJiahong Zhong, Xihui Yu, Zhuomiao Lin
Frontiers in Pharmacology|October 10, 2025
Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramineJiahong Zhong, Zhuomiao Lin, Junling Xue, et al.
Journal of Integrative Neuroscience|January 29, 2026
Roflupram Reduces 6-OHDA-Induced Cellular Damage in SH-SY5Y Cells by Inhibiting PDE4Jiahong Zhong, Xihui Yu, Junling Xue, et al.
Frontiers in Pharmacology|January 21, 2026
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumabZhuomiao Lin, Xihui Yu, Meiqing Yang, et al.
Peerj|August 19, 2025
The role of T cells in the treatment of Parkinson's diseaseZhuomiao Lin, Xihui Yu, Yunming Zhong, et al.
Frontiers in Pharmacology|September 5, 2025
Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)Zhuomiao Lin, Junling Xue, Meiqing Yang, et al.
Frontiers in Pharmacology|January 22, 2025
Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagyZhuomiao Lin, Meiqing Yang, Xihui Yu, et al.
Frontiers in Pharmacology|January 30, 2026
Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS)Xihui Yu, Jiahong Zhong, Zhuomiao Lin, et al.
Frontiers in Pharmacology|May 15, 2025
Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance studyXihui Yu, Jiahong Zhong, Xuemei Zhuang, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Pharmacology|November 11, 2024
Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)Jiahong Zhong, Xihui Yu, Zhuomiao Lin
Peerj|February 3, 2025
Phosphodiesterase 4 inhibition as a novel treatment for strokeJiahong Zhong, Xihui Yu, Zhuomiao Lin
Frontiers in Pharmacology|October 10, 2025
Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramineJiahong Zhong, Zhuomiao Lin, Junling Xue, et al.
Journal of Integrative Neuroscience|January 29, 2026
Roflupram Reduces 6-OHDA-Induced Cellular Damage in SH-SY5Y Cells by Inhibiting PDE4Jiahong Zhong, Xihui Yu, Junling Xue, et al.
Frontiers in Pharmacology|January 21, 2026
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumabZhuomiao Lin, Xihui Yu, Meiqing Yang, et al.
Peerj|August 19, 2025
The role of T cells in the treatment of Parkinson's diseaseZhuomiao Lin, Xihui Yu, Yunming Zhong, et al.
Frontiers in Pharmacology|September 5, 2025
Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)Zhuomiao Lin, Junling Xue, Meiqing Yang, et al.
Frontiers in Pharmacology|January 22, 2025
Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagyZhuomiao Lin, Meiqing Yang, Xihui Yu, et al.
Frontiers in Pharmacology|January 30, 2026
Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS)Xihui Yu, Jiahong Zhong, Zhuomiao Lin, et al.
Frontiers in Pharmacology|May 15, 2025
Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance studyXihui Yu, Jiahong Zhong, Xuemei Zhuang, et al.
Pageof 4